StreetInsider.com News Articles

Form 4 Astrana Health, Inc. For: Aug 14 Filed by: Schmidt David

Tue, 18 Aug 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260818/26944464.html

Form 4 Astrana Health, Inc. For: Aug 14 Filed by: Schmidt David

Tue, 18 Aug 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260818/26944464.html

Form 3 Astrana Health, Inc. For: Aug 07 Filed by: Vong John

Tue, 11 Aug 2026 17:37:00 -0400

si-local-file:///var/storage/secattach/20260811/26907264.html

Form 3 Astrana Health, Inc. For: Aug 07 Filed by: Vong John

Tue, 11 Aug 2026 17:37:00 -0400

si-local-file:///var/storage/secattach/20260811/26907264.html

Form 4 Astrana Health, Inc. For: Aug 07 Filed by: Sobotka Glenn

Tue, 11 Aug 2026 17:10:00 -0400

si-local-file:///var/storage/secattach/20260811/26906977.html

Form 4 Astrana Health, Inc. For: Aug 07 Filed by: Sobotka Glenn

Tue, 11 Aug 2026 17:10:00 -0400

si-local-file:///var/storage/secattach/20260811/26906977.html

Astrana Health, Inc (ASTH) PT Raised to $55 at Truist Securities

Tue, 11 Aug 2026 09:41:59 -0400

(Updated - August 11, 2026 9:41 AM EDT)

Truist Securities analyst Jailendra Singh raised the price target on Astrana Health, Inc (NASDAQ: ASTH) to $55.00 (from $47.00) while maintaining a Buy rating.

The analyst commented: "Investing Today's Outperformance for Tomorrow's Growth; Bottom Line. We came away from the quarter with greater confidence that ASTH’s underlying execution remains strong and that the company is increasingly shifting from integration toward its next phase of growth. Prospect is largely integrated, retention and synergy realization remain solid, and consolidated medical cost trends continue to track favorably, while stable Medicare utilization, AI-enabled operating efficiencies, and continued full-risk

Astrana Health, Inc (ASTH) PT Raised to $55 at Truist Securities

Tue, 11 Aug 2026 09:41:59 -0400

(Updated - August 11, 2026 9:41 AM EDT)

Truist Securities analyst Jailendra Singh raised the price target on Astrana Health, Inc (NASDAQ: ASTH) to $55.00 (from $47.00) while maintaining a Buy rating.

Form 10-Q Astrana Health, Inc. For: Jun 30

Mon, 10 Aug 2026 17:04:00 -0400

http://archive.fast-edgar.com/20260810/AA22U22FZZ2R8TZ2229S2ZYMGPIKEZ22N282

Filed on: August 10, 2026

Form 10-Q Astrana Health, Inc. For: Jun 30

Mon, 10 Aug 2026 17:04:00 -0400

http://archive.fast-edgar.com/20260810/AA22U22FZZ2R8TZ2229S2ZYMGPIKEZ22N282

Filed on: August 10, 2026

Astrana Health, Inc (ASTH) PT Raised to $53 at Barclays

Fri, 07 Aug 2026 04:53:27 -0400

Barclays analyst Andrew Mok raised the price target on Astrana Health, Inc (NASDAQ: ASTH) to $53.00 (from $50.00) while maintaining a Overweight rating.

Form 8-K Astrana Health, Inc. For: Aug 06

Thu, 06 Aug 2026 16:12:00 -0400

si-local-file:///var/storage/secattach/20260806/26884049.html

Form 8-K Astrana Health, Inc. For: Aug 06

Thu, 06 Aug 2026 16:12:00 -0400

si-local-file:///var/storage/secattach/20260806/26884049.html

ASTH (ASTH) Tops Q2 EPS by 47c

Thu, 06 Aug 2026 16:11:37 -0400

ASTH (NASDAQ: ASTH) reported Q2 EPS of $0.80, $0.47 better than the analyst estimate of $0.33. Revenue for the quarter came in at $972.5 million versus the consensus estimate of $985.72 million.

For earnings history and earnings-related data on ASTH (ASTH) click here.

Astrana Health, Inc. Reports Second Quarter 2026 Results

Thu, 06 Aug 2026 16:05:00 -0400

Company to Host Conference Call on Thursday, August 6, 2026, at 2:30 p.m. PT/5:30 p.m. ET

Reports revenue of $972.5 million, up 49% year-over-year, net income of $18.5 million, up 81% year-over-year, and adjusted EBITDA ⁽¹⁾ of $68.9 million, up 43% year-over-year for the three months ended June 30, 2026
Reports net cash provided by operating activities of $100.8 million and free cash flow ⁽²⁾ of $92.9 million for the six months ended June 30, 2026